BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma
Source: 2minute Medicine, April 2025
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the treatment arm.
2. At 3 months, ctDNA detection had a sensitivity of 59%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 71%.
